Literature DB >> 33139265

International Consensus Definition of DNA Methylation Subgroups in Juvenile Myelomonocytic Leukemia.

Maximilian Schönung1,2, Julia Meyer3, Hideki Muramatsu4, Christian Flotho5,6, Elliot Stieglitz3,7, Daniel B Lipka8,9, Peter Nöllke5, Adam B Olshen10,7, Mark Hartmann1, Norihiro Murakami4, Manabu Wakamatsu4, Yusuke Okuno11, Christoph Plass12, Mignon L Loh3,7, Charlotte M Niemeyer5,6.   

Abstract

PURPOSE: Known clinical and genetic markers have limitations in predicting disease course and outcome in juvenile myelomonocytic leukemia (JMML). DNA methylation patterns in JMML have correlated with outcome across multiple studies, suggesting it as a biomarker to improve patient stratification. However, standardized approaches to classify JMML on the basis of DNA methylation patterns are lacking. We, therefore, sought to define an international consensus for DNA methylation subgroups in JMML and develop classification methods for clinical implementation. EXPERIMENTAL
DESIGN: Published DNA methylation data from 255 patients with JMML were used to develop and internally validate a classifier model. Accuracy across platforms (EPIC-arrays and MethylSeq) was tested using a technical validation cohort (32 patients). The suitability of both methods for single-patient classification was demonstrated using an independent cohort (47 patients).
RESULTS: Analysis of pooled, published data established three DNA methylation subgroups as a de facto standard. Unfavorable prognostic parameters (PTPN11 mutation, elevated fetal hemoglobin, and older age) were significantly enriched in the high methylation (HM) subgroup. A classifier was then developed that predicted subgroups with 98% accuracy across different technological platforms. Applying the classifier to an independent validation cohort confirmed an association of HM with secondary mutations, high relapse incidence, and inferior overall survival (OS), while the low methylation subgroup was associated with a favorable disease course. Multivariable analysis established DNA methylation subgroups as the only significant factor predicting OS.
CONCLUSIONS: This study provides an international consensus definition for DNA methylation subgroups in JMML. We developed and validated methods which will facilitate the design of risk-stratified clinical trials in JMML. ©2020 American Association for Cancer Research.

Entities:  

Mesh：

Year:  2020        PMID： 33139265      PMCID： PMC7785676          DOI： 10.1158/1078-0432.CCR-20-3184

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   13.801


  39 in total

1.  The sva package for removing batch effects and other unwanted variation in high-throughput experiments.

Authors:  Jeffrey T Leek; W Evan Johnson; Hilary S Parker; Andrew E Jaffe; John D Storey
Journal:  Bioinformatics       Date:  2012-01-17       Impact factor: 6.937

Review 2.  Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia.

Authors:  Franco Locatelli; Mattia Algeri; Pietro Merli; Luisa Strocchio
Journal:  Expert Rev Hematol       Date:  2018-01-03       Impact factor: 2.929

3.  Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia.

Authors:  M F Johan; D T Bowen; M E Frew; A C Goodeve; J T Reilly
Journal:  Br J Haematol       Date:  2005-04       Impact factor: 6.998

4.  Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome.

Authors:  Christiane Olk-Batz; Anna R Poetsch; Peter Nöllke; Rainer Claus; Manuela Zucknick; Inga Sandrock; Tania Witte; Brigitte Strahm; Henrik Hasle; Marco Zecca; Jan Stary; Eva Bergstraesser; Barbara De Moerloose; Monika Trebo; Marry M van den Heuvel-Eibrink; Dorota Wojcik; Franco Locatelli; Christoph Plass; Charlotte M Niemeyer; Christian Flotho
Journal:  Blood       Date:  2011-03-15       Impact factor: 22.113

5.  Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations.

Authors:  Kazuyuki Matsuda; Akira Shimada; Nao Yoshida; Atsushi Ogawa; Akihiro Watanabe; Shuhei Yajima; Susumu Iizuka; Kazutoshi Koike; Fumio Yanai; Keiichiro Kawasaki; Masakatsu Yanagimachi; Akira Kikuchi; Yoshitoshi Ohtsuka; Eiko Hidaka; Kazuyoshi Yamauchi; Miyuki Tanaka; Ryu Yanagisawa; Yozo Nakazawa; Masaaki Shiohara; Atsushi Manabe; Seiji Kojima; Kenichi Koike
Journal:  Blood       Date:  2007-03-01       Impact factor: 22.113

Review 6.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

7.  Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications.

Authors:  Felix Krueger; Simon R Andrews
Journal:  Bioinformatics       Date:  2011-04-14       Impact factor: 6.937

8.  GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers.

Authors:  Craig H Mermel; Steven E Schumacher; Barbara Hill; Matthew L Meyerson; Rameen Beroukhim; Gad Getz
Journal:  Genome Biol       Date:  2011-04-28       Impact factor: 13.583

9.  Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia.

Authors:  Elliot Stieglitz; Tali Mazor; Adam B Olshen; Huimin Geng; Laura C Gelston; Jon Akutagawa; Daniel B Lipka; Christoph Plass; Christian Flotho; Farid F Chehab; Benjamin S Braun; Joseph F Costello; Mignon L Loh
Journal:  Nat Commun       Date:  2017-12-19       Impact factor: 14.919

10.  Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma.

Authors:  Alan Mackay; Anna Burford; Diana Carvalho; Elisa Izquierdo; Janat Fazal-Salom; Kathryn R Taylor; Lynn Bjerke; Matthew Clarke; Mara Vinci; Meera Nandhabalan; Sara Temelso; Sergey Popov; Valeria Molinari; Pichai Raman; Angela J Waanders; Harry J Han; Saumya Gupta; Lynley Marshall; Stergios Zacharoulis; Sucheta Vaidya; Henry C Mandeville; Leslie R Bridges; Andrew J Martin; Safa Al-Sarraj; Christopher Chandler; Ho-Keung Ng; Xingang Li; Kun Mu; Saoussen Trabelsi; Dorra H'mida-Ben Brahim; Alexei N Kisljakov; Dmitry M Konovalov; Andrew S Moore; Angel Montero Carcaboso; Mariona Sunol; Carmen de Torres; Ofelia Cruz; Jaume Mora; Ludmila I Shats; João N Stavale; Lucas T Bidinotto; Rui M Reis; Natacha Entz-Werle; Michael Farrell; Jane Cryan; Darach Crimmins; John Caird; Jane Pears; Michelle Monje; Marie-Anne Debily; David Castel; Jacques Grill; Cynthia Hawkins; Hamid Nikbakht; Nada Jabado; Suzanne J Baker; Stefan M Pfister; David T W Jones; Maryam Fouladi; André O von Bueren; Michael Baudis; Adam Resnick; Chris Jones
Journal:  Cancer Cell       Date:  2017-09-28       Impact factor: 31.743
View more
  9 in total

Review 1.  Treatment advances for pediatric and adult onset neoplasms with monocytosis.

Authors:  Kristen B McCullough; Alexis K Kuhn; Mrinal M Patnaik
Journal:  Curr Hematol Malig Rep       Date:  2021-03-16       Impact factor: 3.952

Review 2.  Genomic and Epigenomic Landscape of Juvenile Myelomonocytic Leukemia.

Authors:  Claudia Fiñana; Noel Gómez-Molina; Sandra Alonso-Moreno; Laura Belver
Journal:  Cancers (Basel)       Date:  2022-03-04       Impact factor: 6.639

3.  Abnormal B-Cell Maturation and Increased Transitional B Cells in CBL Syndrome.

Authors:  Francesco Saettini; Tiziana Angela Coliva; Francesca Vendemini; Marta Galbiati; Cristina Bugarin; Riccardo Masetti; Daniele Moratto; Marco Chiarini; Fabiola Guerra; Maria Iascone; Raffaele Badolato; Giovanni Cazzaniga; Charlotte Niemeyer; Christian Flotho; Andrea Biondi
Journal:  Front Pediatr       Date:  2022-07-28       Impact factor: 3.569

Review 4.  Allogeneic Hematopoietic Stem Cell Transplantation for Mixed or Overlap Myelodysplastic/Myeloproliferative Disorders.

Authors:  Argiris Symeonidis; Spiros Chondropoulos; Evgenia Verigou; Vasileios Lazaris; Alexandra Kourakli; Panagiotis Tsirigotis
Journal:  Front Oncol       Date:  2022-08-05       Impact factor: 5.738

5.  Clinical parameter-based prediction of DNA methylation classification generates a prediction model of prognosis in patients with juvenile myelomonocytic leukemia.

Authors:  Takahiro Imaizumi; Julia Meyer; Manabu Wakamatsu; Hironobu Kitazawa; Norihiro Murakami; Yusuke Okuno; Taro Yoshida; Daichi Sajiki; Asahito Hama; Seiji Kojima; Yoshiyuki Takahashi; Mignon Loh; Elliot Stieglitz; Hideki Muramatsu
Journal:  Sci Rep       Date:  2022-08-30       Impact factor: 4.996

6.  Identification of cystic fibrosis transmembrane conductance regulator as a prognostic marker for juvenile myelomonocytic leukemia via the whole-genome bisulfite sequencing of monozygotic twins and data mining.

Authors:  Tian-Tian Yi; Jie-Ming Yu; Yi-Yang Liang; Si-Qi Wang; Guan-Chuan Lin; Xue-Dong Wu
Journal:  Transl Pediatr       Date:  2022-09

7.  Juvenile myelomonocytic leukemia in the molecular era: a clinician's guide to diagnosis, risk stratification, and treatment.

Authors:  Astrid Wintering; Christopher C Dvorak; Elliot Stieglitz; Mignon L Loh
Journal:  Blood Adv       Date:  2021-11-23

8.  Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia.

Authors:  Anna Hecht; Julia A Meyer; Astrid Behnert; Eric Wong; Farid Chehab; Adam Olshen; Aaron Hechmer; Catherine Aftandilian; Rukhmi Bhat; Sung Won Choi; Satheesh Chonat; Jason E Farrar; Mark Fluchel; Haydar Frangoul; Jennifer H Han; Edward A Kolb; Dennis J Kuo; Margaret L MacMillan; Luke Maese; Kelly W Maloney; Aru Narendran; Benjamin Oshrine; Kirk R Schultz; Maria L Sulis; David Van Mater; Sarah K Tasian; Wolf-Karsten Hofmann; Mignon L Loh; Elliot Stieglitz
Journal:  Haematologica       Date:  2022-01-01       Impact factor: 9.941

9.  Simple and robust methylation test for risk stratification of patients with juvenile myelomonocytic leukemia.

Authors:  Hironobu Kitazawa; Yusuke Okuno; Hideki Muramatsu; Kosuke Aoki; Norihiro Murakami; Manabu Wakamatsu; Kyogo Suzuki; Kotaro Narita; Shinsuke Kataoka; Daisuke Ichikawa; Motoharu Hamada; Rieko Taniguchi; Nozomu Kawashima; Eri Nishikawa; Atsushi Narita; Nobuhiro Nishio; Asahito Hama; Mignon L Loh; Elliot Stieglitz; Seiji Kojima; Yoshiyuki Takahashi
Journal:  Blood Adv       Date:  2021-12-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.